Cargando…
No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer
BACKGROUND: The prognosis of gastric cancer in an advanced stage remains poor. The exact efficacy of the use of intraoperative sustained-release chemotherapy with 5-fluorouracil (5-FU) in advanced-stage gastric cancer is still unelucidated. AIM: To explore the long-term survival benefit of using sus...
Autores principales: | Wu, Yun-Zi, Wu, Ming, Zheng, Xiao-Hao, Wang, Bing-Zhi, Xue, Li-Yan, Ding, Shi-Kang, Yang, Lin, Ren, Jian-Song, Tian, Yan-Tao, Xie, Yi-Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594009/ https://www.ncbi.nlm.nih.gov/pubmed/36304092 http://dx.doi.org/10.3748/wjg.v28.i38.5589 |
Ejemplares similares
-
Prognostic effect of excessive chemotherapy cycles for stage II and III gastric cancer patients after D2 + gastrectomy
por: Li, Yi-Fan, et al.
Publicado: (2023) -
Changing trends of clinicopathologic features and survival duration after surgery for gastric cancer in Northeast China
por: Zhai, Zhao, et al.
Publicado: (2020) -
Incorporation of perigastric tumor deposits into the TNM staging system for primary gastric cancer
por: Li, Yang, et al.
Publicado: (2023) -
Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis
por: Guo, Jian-Hai, et al.
Publicado: (2017) -
Increased 5-hydroxymethylcytosine is a favorable prognostic factor of Helicobacter pylori-negative gastric cancer patients
por: Fu, Ying-Li, et al.
Publicado: (2022)